Michael Okunewitch
Stock Analyst at Maxim Group
(0.74)
# 3,961
Out of 4,981 analysts
27
Total ratings
29.17%
Success rate
-10.57%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANEB Anebulo Pharmaceuticals | Downgrades: Hold | n/a | $2.46 | - | 3 | Jul 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $4.90 | +614.29% | 2 | May 29, 2025 | |
| CTOR Citius Oncology | Downgrades: Hold | n/a | $1.84 | - | 2 | May 23, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $6.75 | +77.78% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $2.82 | +892.91% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.58 | +788.89% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.35 | +122.22% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.20 | +233.33% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.54 | +2,125.52% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $0.76 | +692.08% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $1.30 | +823.08% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.51 | +1,489.40% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.61 | +589.66% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.35 | +86,070.21% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $17.14 | +45.86% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.52 | +294.74% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.65 | +437.63% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.14 | +8,671.93% | 1 | Nov 30, 2021 |
Anebulo Pharmaceuticals
Jul 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.46
Upside: -
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $4.90
Upside: +614.29%
Citius Oncology
May 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.84
Upside: -
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $6.75
Upside: +77.78%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $2.82
Upside: +892.91%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.58
Upside: +788.89%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.35
Upside: +122.22%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.20
Upside: +233.33%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.54
Upside: +2,125.52%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.76
Upside: +692.08%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $1.30
Upside: +823.08%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.51
Upside: +1,489.40%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.61
Upside: +589.66%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.35
Upside: +86,070.21%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $17.14
Upside: +45.86%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.52
Upside: +294.74%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $4.65
Upside: +437.63%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $1.14
Upside: +8,671.93%